COPENHAGEN, May 23, 2014 (GLOBE NEWSWIRE) -- //Investor News
Zealand to present at three global healthcare investor conferences in June 2014
Copenhagen, 23 May 2014 - Zealand Pharma A/S (Zealand) (NASDAQ OMX Copenhagen: ZEAL)informs that the company will participate in the following three global healthcare investor conferences in June 2014.
Jefferies Global Healthcare Conference, New York City (2-5 June)
Date and time of Zealand's presentation: Thursday 5 June 2014 at 9.30am EDT (3.30pm CET)
Goldman Sachs 35th Annual Global Healthcare Conference, Rancho Palos Verdes, California (10-12 June)
Date and time of Zealand's presentation: Wednesday 11 June 2014 at 3:20pm PDT (Thursday 12 June 00:20 CET)
Citi European Healthcare One-on-One Conference, London (19-20 June)
Zealand's management team will host one-on-one and group meetings with investors on Thursday 19 and Friday 20 June 2014.
At these three events, David Solomon, President and Chief Executive Officer, will present an update on Zealand and the status and outlook for the main products in the company's portfolio of peptide medicines. These include Lyxumia(r) (lixisenatide), a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, and the first medicine from Zealand's pipeline to have reached the market. Marketed globally by Sanofi, Lyxumia(r) was launched in the first markets in 2013 and commercial roll-out is ongoing country by country. To follow Lyxumia(r), Zealand is advancing a pipeline of six clinical (Phases I - III) and several preclinical peptide therapeutics, including both proprietary and partnered programs.
Please note that no new financial or other material new information relating to Zealand will be disclosed at the above listed conferences.
For further information, please contact:
Hanne Leth Hillman, Vice President,
Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: firstname.lastname@example.org
Zealand Pharma A/S (Zealand) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and a mature portfolio of therapeutic products, which are all based on internal inventions. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, marketed as Lyxumia(r) under a license agreement with Sanofi. Lyxumia(r) is approved in several countries globally, including Europe and Japan. In the US, submission of an NDA is expected in 2015, after completion of a cardiovascular outcome study, ELIXA. A once-daily single injection combination of Lyxumia(r) and Lantus(r) (LixiLan) is in Phase III development with planned first regulatory filing in end 2015.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com
Follow us on Twitter@ZealandPharma
Source:Zealand Pharma A/S